Atom Therapeutics Co., Ltd
Clinical trials sponsored by Atom Therapeutics Co., Ltd, explained in plain language.
-
New drug aims to melt artery plaque in heart patients
Disease control Recruiting nowThis study tests an experimental drug called ABP-745 in 200 adults with atherosclerosis (hardening of the arteries due to plaque buildup). The goal is to see if it can reduce plaque in the arteries better than a placebo. Participants will receive the drug or placebo for 52 weeks,…
Phase: PHASE2 • Sponsor: Atom Therapeutics Co., Ltd • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New gout drug aims to beat standard treatment in pain showdown
Symptom relief Recruiting nowThis study tests a new medicine called ABP-745 to see if it reduces pain and swelling from an acute gout flare better than the standard drug colchicine or a placebo. About 380 adults aged 18 to 70 who have had at least two gout flares in the past year will take part. The main goa…
Phase: PHASE2 • Sponsor: Atom Therapeutics Co., Ltd • Aim: Symptom relief
Last updated May 14, 2026 12:06 UTC
-
New gout drug combo under the microscope: ABP-671 meets allopurinol
Knowledge-focused Recruiting nowThis study looks at how a new drug, ABP-671, interacts with the standard gout medication allopurinol. About 20 adults with gout who are already taking allopurinol will receive ABP-671 as well. Researchers will measure drug levels in the blood to see if there are any interactions,…
Phase: PHASE1 • Sponsor: Atom Therapeutics Co., Ltd • Aim: Knowledge-focused
Last updated May 17, 2026 07:38 UTC